FDA CRL - Teva Women's Health Inc.

Teva Women’s Health, Inc. received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA 201110) for a progesterone vaginal ring, indicating the application cannot be approved in its current form. The regulatory decision follows a review of the application and recent inspections. Key deficiencies highlighted issues across multiple areas. Product quality concerns included foreign particulate contamination in manufacturing batches observed during a prior approval inspection, necessitating a root cause investigation and corrective actions demonstrated by producing particulate-free batches. The FDA also required amendments to drug substance specifications to include particle size distribution and drug product specifications for visual particulate absence and microbiological examination. Analytical methods for impurity detection also require further validation and revised acceptance criteria. Clinically, the application lacked sufficient efficacy data for women aged 35-42, who represent a significant portion of the target infertile population. The FDA recommends an adequately powered, randomized, active-controlled clinical trial for this subgroup, or alternatively, a labeling limitation with a post-marketing commitment. Furthermore, deficiencies were noted during inspections of the Northvale, NJ testing facility and Cincinnati, OH manufacturing facility, requiring satisfactory resolution. The company is also mandated to provide a comprehensive safety update, incorporating new data and worldwide experience. Teva must address these issues and resubmit the application or take other actions within one year under 21 CFR 314.110.